New FDA Web Page Aims To Clarify Position On 3D Printing
As industry awaits more guidance and clarification from US FDA about its regulatory oversight of 3D-printed devices, the agency is attempting to be more transparent with a new web page that outlines some of its current thinking and efforts on the topic.
You may also be interested in...
Attorneys at Reed Smith have released a white paper that attempts to tackle the legal uncertainties facing 3D printing of medical devices. They tackle issues including product liability, intellectual property and quality management. Also: Listen to our podcast interview with one key contributor to the report.
A draft guidance issued by FDA on additive manufacturing, or 3-D printing, of medical devices is meant to be a starting point for an industry that is growing exponentially. The document outlines recommendations on topics such as device design, software considerations and material testing requirements.
A new market report estimates the global health-care revenue from 3D-printed medical devices is likely to grow to almost $3 billion by 2022. FDA has a keen interest in understanding how to oversee production of 3D-printed devices that can be made anywhere, and device-makers are interested in the technology to develop products personalized to patients.